Yield10 Bioscience SEC Filings

Type
Report
Date
No documents available

Yield10 Bioscience Documents 2026

This page contains all official documents and SEC filings for Yield10 Bioscience stock (YTENQ, ISIN: US98585K8541). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Yield10 Bioscience's regulatory filings.

Yield10 Bioscience Stock analysis

Yield10 Bioscience Yield10 Bioscience develops Camelina sativa as a platform crop for low carbon sustainable seed products, including Camelina oil for biofuel feedstock, Omega-3 oils for nutrition, and PHA Bioplastics for biodegradable packaging. The company uses its TraitFactory platform to discover genetic traits for agriculture and food industries, focusing on herbicide tolerance and disease resistance in Camelina germplasm. Its products target petroleum replacement markets, food and nutrition sectors, and animal feed markets, with development pipelines focused on improving Camelina varieties. The company's primary products are Camelina oil, Omega-3 oils, and PHA Bioplastics, sold to markets addressing petroleum replacement, nutrition, and sustainable packaging needs. Camelina sativa serves as the core crop for all seed product development, with TraitFactory enabling trait discovery for agricultural and food applications. The firm targets industrial buyers in biofuel, nutrition, and packaging industries seeking sustainable alternatives to petroleum-based products. Yield10 Bioscience's revenue streams come from the sale of Camelina-based products to companies in the biofuel, nutrition, and packaging sectors. The company focuses on developing high-value genetic traits through TraitFactory, which are integrated into Camelina varieties for large-scale production of seed products. Its development pipeline emphasizes traits like herbicide tolerance and disease resistance to enhance crop performance and market appeal.